This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Uncategorised Disease
  • /
  • Augmented post–remission therapy for a minimal res...

Augmented post–remission therapy for a minimal residual disease–defined high–risk subgroup of children and young people with clinical standard–risk and intermediate–risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial

Read time: 1 mins
Published:25th Mar 2020
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest